Global HER2 Antibodies Market Estimated for Rapid Surge at CAGR of 8.6% during 2017-2025

Published on : Sep 11, 2017

Albany, New York, September 11, 2017: According to a recent analysis, growing awareness regarding the prevalence of HER2 positive breast cancer, has reinvigorated the demand for HER2 antibodies in the global market. Market Research Hub (MRH) has freshly broadcasted a new study to its wide repository, which is titled as “HER2 Antibodies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025”. The report covers all the prevalent trends and technologies playing a major role in the growth of the Anti-Drone market over the forecast period. It also highlights various drivers, restraints, and opportunities expected to influence the market growth during the said period.

Initially, the study starts be presenting an in-depth overview of the HER2 antibodies market so as to enlighten the readers about the motive of the research. The following section leads to current and future prospects of the HER2 antibodies market based on type of treatment drugs and geography. As per the analyst’s key findings, one of the biggest and most exciting advances in recent history in the fight against breast cancer is a drug called Herceptin. The drug has shown to be very successful against certain types of advanced breast cancers. HER2 breast cancer is one of the aggressive types of breast cancer, caused due to over-expression of the HER2 protein. Breast cancers that overexpress the HER2 protein (known as HER2+) make up about 20% of the cases.

In the recent times, increasing incidence of breast cancer is expected to lead to increase in demand for targeted therapies and boost the growth of the HER2 antibodies market during the forecast period. As per the figures, the demand in the global HER2 antibodies market is projected to increment at a robust CAGR of 8.6% during the forecast period of 2017 to 2025. Additionally, the report provides estimated market size in terms of US$ Mn for each type of treatment drug, and geography for the period 2016 to 2025, considering the macro and micro environmental factors. The research displays that the market is estimated to be worth US$ 21,669.1 mn from US$ 10,087.8 mn by the end of 2025.

Moving further, the HER2 antibodies market has been bifurcated into the prime regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Of these, the market in North America and Europe is expected to dwindle during the forecast period. In terms of revenue, U.S. is the most profitable country-wide market for HER2 antibodies in North America. Apart from that, On the basis of type of therapeutic drugs, the market has been segmented into Trastuzumab, Everolimus Lapatinib, Pertuzumab and Ado-trastuzumab emtansine. Amongst, Trastuzumab accounted for the most considerable amount of the market at 62.1% shares terms of revenue.

Major companies profiled in the HER2 antibodies market report are Pfizer, Inc., Genentech Inc. (F. Hoffmann-La Roche Ltd.), Celltrion, Inc., Novartis AG, Abnova Corporation, InvivoGen, Biocon Limited, and Bio-Techne (Novus Biologicals, LLC) and others.

Request a Sample with TOC in a PDF format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top